CagriSema
cagrilintide + semaglutide · Novo Nordisk
Two molecules in one injection: amylin analogue plus semaglutide.
Selected study results
REDEFINE 1Mean body-weight changeBody weight decreased 20.4% · 68 weeks · Phase 3
Mean body-weight change · 68 weeks
Study focus: Weight management without type 2 diabetes
68-week Phase 3 trial in adults without type 2 diabetes; treatment-policy analysis.
Adults with obesity, or overweight and an obesity-related complication · Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly vs placebo · Trial N=3417 · Treatment-policy estimand. Results & methods ↗
- REDEFINE 1 · post hoc early-response analysisAmong participants with less than 5% loss at week 8 and observed on-treatment week-68 data, mean weight loss was 17.8% and 37.2% achieved at least 20% loss. This selected, observed-data analysis is hypothesis-generating and does not validate a stopping rule. Follow-up source ↗
Gastrointestinal adverse events: 79.6% with combination versus 39.9% with placebo. The adherence-based estimate is a separate analysis.
REDEFINE 9Mean body-weight reductionBody weight decreased 21% · 68 weeks · Phase 3b
Mean body-weight reduction · 68 weeks
Study focus: Lower-dose weight management
Lower-dose CagriSema versus placebo in a 68-week randomized, double-blind trial.
Adults with obesity, or overweight with an obesity-related complication, without diabetes · Cagrilintide/semaglutide 1.0/1.0 or 1.7/1.7 mg weekly versus placebo · Trial N=309 · Efficacy estimand, assuming adherence; published trial reported by sponsor. Results & methods ↗ · Publication ↗
| Weekly regimen | Efficacy estimand | Treatment-regimen estimand |
|---|---|---|
| 1.7/1.7 mg | 20.7% | 19.4% |
| 1.0/1.0 mg | 21.0% | 18.6% |
| Placebo | 2.0% | 4.6% |
- Treatment-regimen estimandIncludes the effect of treatment discontinuation and use of weight-management rescue interventions. It is separate from the adherence-based efficacy estimand.
The two doses were tested against placebo; similar averages do not establish dose equivalence. Gastrointestinal events were most frequent and mainly mild to moderate. Adverse-event discontinuation was 2.9%, 4.9% and 4.9% with 1.7/1.7 mg, 1.0/1.0 mg and placebo, respectively.
REDEFINE 2Mean body-weight changeBody weight decreased 13.7% · 68 weeks · Phase 3
Mean body-weight change · 68 weeks
Study focus: Weight management with type 2 diabetes
68-week Phase 3 weight-management trial in adults with type 2 diabetes.
Adults with BMI ≥27 and type 2 diabetes, baseline HbA1c 7–10% · CagriSema 2.4/2.4 mg weekly vs placebo · Trial N=1206 · Treatment-policy estimand. Results & methods ↗
REDEFINE 4Mean body-weight changeBody weight decreased 20.2% · 84 weeks · Phase 3
Mean body-weight change · 84 weeks
Study focus: Comparative weight management
Head-to-head: weight-loss noninferiority was not demonstrated.
Adults with obesity and at least one complication · CagriSema 2.4/2.4 mg vs tirzepatide 15 mg weekly · Trial N=809 · Treatment-regimen estimand; sponsor topline. Results & methods ↗
Open-label design. Efficacy-estimand reductions were 23.0% and 25.5%, respectively.
REDEFINE 5Mean body-weight changeBody weight decreased 18.4% · 68 weeks · Phase 3
Mean body-weight change · 68 weeks
Study focus: Comparative weight management · Japan/Taiwan
Combination produced greater weight reduction than semaglutide alone.
Adults in Japan and Taiwan meeting regional BMI/complication criteria; 24% had type 2 diabetes · CagriSema 2.4/2.4 mg vs semaglutide 2.4 mg weekly · Trial N=331 · Published primary estimated mean change. Results & methods ↗
Diabetes-focused studies
These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.
REIMAGINE 1Mean body-weight changeBody weight decreased 13.6% · 40 weeks · Phase 3
Mean body-weight change · 40 weeks
Study focus: Weight change in type 2 diabetes
HbA1c decreased 1.8 vs 0.4 percentage points.
Type 2 diabetes inadequately controlled with diet and exercise · CagriSema 2.4/2.4 mg weekly vs placebo · Trial N=189 · Treatment-regimen estimand; published trial reported by sponsor. Results & methods ↗ · Publication ↗
REIMAGINE 2Mean body-weight changeBody weight decreased 12.9% · 68 weeks · Phase 3
Mean body-weight change · 68 weeks
Study focus: Weight change in type 2 diabetes
HbA1c decreased 1.80 vs 1.68 percentage points against semaglutide 2.4 mg.
Type 2 diabetes on metformin with or without an SGLT2 inhibitor · CagriSema 2.4/2.4 mg weekly vs semaglutide 2.4 mg · Trial N=2713 · Treatment-regimen estimand; published trial reported by sponsor. Results & methods ↗ · Publication ↗
REIMAGINE 3Mean body-weight changeBody weight decreased 11.3% · 40 weeks · Phase 3
Mean body-weight change · 40 weeks
Study focus: Weight change in type 2 diabetes
HbA1c decreased 2.26 vs 0.80 percentage points. Placebo weight increased.
Type 2 diabetes treated with basal insulin, with or without metformin · CagriSema 2.4/2.4 mg weekly vs placebo · Trial N=274 · Treatment-regimen estimand; published trial reported by sponsor. Results & methods ↗ · Publication ↗
REIMAGINE 4Mean body-weight changeBody weight decreased 15.2% · 68 weeks · Phase 3
Mean body-weight change · 68 weeks
Study focus: Weight change in type 2 diabetes
Weight noninferiority met; HbA1c noninferiority not met. Open-label trial.
Type 2 diabetes on metformin with or without an SGLT2 inhibitor · CagriSema 2.4/2.4 mg vs tirzepatide 15 mg weekly · N not included in this summary · Efficacy estimand; sponsor report. Results & methods ↗
REIMAGINE 5Mean body-weight changeBody weight decreased 12.4% · 60 weeks · Phase 3
Mean body-weight change · 60 weeks
Study focus: Weight change in type 2 diabetes
Weight superiority and HbA1c noninferiority met at these specific doses.
Type 2 diabetes on metformin, an SGLT2 inhibitor or both · CagriSema 1.0/1.0 mg vs tirzepatide 5 mg weekly · N not included in this summary · Efficacy estimand; sponsor topline. Results & methods ↗
CagriSema Phase 2 · type 2 diabetesMean body-weight changeBody weight decreased 15.6% · 32 weeks · Phase 2
Mean body-weight change · 32 weeks
Study focus: Glycemic control and weight in type 2 diabetes
Adults with type 2 diabetes and BMI ≥27 kg/m² on metformin with or without an SGLT2 inhibitor · Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly vs semaglutide 2.4 mg weekly · Trial N=92 · Published estimated mean changes; active-controlled randomized trial. Results & methods ↗ · Publication ↗
- Third arm and primary endpoint · same studyCagrilintide alone reduced weight by 8.1%. HbA1c changes were −2.2, −1.8 and −0.9 percentage points with CagriSema, semaglutide and cagrilintide, respectively.
Small active-controlled trial with three arms and no placebo arm. HbA1c was the primary endpoint; the HbA1c difference versus semaglutide was not statistically significant.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: The U.S. weight-management application remains under review. Novo’s Q2 2026 pipeline update lists REDEFINE 11 and a separate higher-dose obesity program.
Next: REDEFINE 11 readout, expected in the first half of 2027, and further regulatory updates.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies14 records
Cagrilintide / CagriSema · pediatric study
Pediatric weight managementShared protocol evaluating cagrilintide and CagriSema in children/adolescents; one protocol linked from both relevant profiles. Investigational pediatric use.
CagriSema high-dose obesity program
Weight managementSeparate higher-dose development program; Novo’s Q2 2026 materials list it alongside Phase 3 obesity studies. No outcome data reported.
REDEFINE 1
Weight managementAdults with obesity, or overweight and an obesity-related complication; 68 weeks.
REDEFINE 11
Weight management and maintenance80-week placebo-controlled study in adults with obesity; includes an extension studying maintenance of weight loss. Novo expects results in the first half of 2027.
REDEFINE 2
Weight management with type 2 diabetesAdults with BMI ≥27 and type 2 diabetes, baseline HbA1c 7–10%; 68 weeks.
REDEFINE 4
Weight managementAdults with obesity and at least one complication; 84 weeks.
REDEFINE 5
Weight management with type 2 diabetesAdults in Japan and Taiwan meeting regional BMI/complication criteria; 24% had type 2 diabetes; 68 weeks.
REDEFINE 8
Body composition and weight maintenance104-week study in adults with obesity, including body-composition assessment and an extension focused on weight-loss maintenance or dose tapering.
REDEFINE 9
Weight management309 adults without diabetes randomized to CagriSema 1.7/1.7 mg, 1.0/1.0 mg or placebo for 68 weeks. Efficacy and treatment-regimen estimands are reported separately.
REIMAGINE 1
Glycemic control and weight outcomes in type 2 diabetesType 2 diabetes inadequately controlled with diet and exercise; 40 weeks.
REIMAGINE 2
Glycemic control and weight outcomes in type 2 diabetesType 2 diabetes on metformin with or without an SGLT2 inhibitor; 68 weeks.
REIMAGINE 3
Glycemic control and weight outcomes in type 2 diabetesType 2 diabetes treated with basal insulin, with or without metformin; 40 weeks.
REIMAGINE 4
Glycemic control and weight outcomes in type 2 diabetesType 2 diabetes on metformin with or without an SGLT2 inhibitor; 68 weeks.
REIMAGINE 5
Glycemic control and weight outcomes in type 2 diabetesType 2 diabetes on metformin, an SGLT2 inhibitor or both; 60 weeks.
Phase 2 studies1 record
CagriSema Phase 2 type 2 diabetes trial
Glycemic control and weight in type 2 diabetesPublished 32-week active-controlled study with 92 participants; primary HbA1c and secondary body-weight endpoints.
Related conditions and outcomes
Phase 3 studies1 record
REDEFINE 3
Cardiovascular outcomesEvent-driven cardiovascular outcomes in adults with established cardiovascular disease, with or without type 2 diabetes.
